Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7780]

FDA approves erlotinib with EGFR mutation test for advanced NSCLC

FDA approves erlotinib with EGFR mutation test for advanced NSCLC

FDA approves radium-223 dichloride for bone metastases from castration-resistant prostate cancer

FDA approves radium-223 dichloride for bone metastases from castration-resistant prostate cancer

Scientists define a new mechanism leading to tumour hypoxia

Scientists define a new mechanism leading to tumour hypoxia

EMCTO 2013: Different survival outcome following diagnosis of metastatic bone disease shown for EGFR mutated NSCLC patients in small retrospective study

EMCTO 2013: Different survival outcome following diagnosis of metastatic bone disease shown for EGFR mutated NSCLC...

EMCTO 2013: Meta-analysis slightly favours platinum-based first-line treatment in patients with advanced/metastatic NSCLC

EMCTO 2013: Meta-analysis slightly favours platinum-based first-line treatment in patients with advanced...

EMCTO 2013: First-line gefitinib effective and well tolerated in Caucasian patients with EGFR mutation-positive NSCLC

EMCTO 2013: First-line gefitinib effective and well tolerated in Caucasian patients with EGFR mutation-positive...

EMCTO 2013: Enobosarm improves muscle wasting experienced by patients with NSCLC

EMCTO 2013: Enobosarm improves muscle wasting experienced by patients with NSCLC

EMCTO 2013: Findings support the value of tumour rebiopsy in NSCLC patients

EMCTO 2013: Findings support the value of tumour rebiopsy in NSCLC patients

IMPAKT 2013: New prospects for targeted therapies for breast cancer

IMPAKT 2013: New prospects for targeted therapies for breast cancer

Experimental drug inhibits growth in all stages of common kidney cancer

Experimental drug inhibits growth in all stages of common kidney cancer

More from ecancer